Salarius amends merger deal with Decoy; sets preferred conversion floor at $3.75

Decoy Therapeutics Inc.

Fifth Amendment to Merger Agreement sets initial conversion price at $10.50/share for Series A & B Preferred.
Price protection adjusted using spread between $10.50 baseline and any dilutive subsequent financing.
Floor price of $3.75/share set as lowest conversion price in price protection calculations.
Series B Preferred redemption price changed to $10.50 multiplied by 1,000 per share.
All other Merger Agreement terms remain in full force and effect.

item 1.01item 3.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.